collection
MENU ▼
Read by QxMD icon Read
search

Neuroimmunology

shared collection
65 papers 0 to 25 followers
https://www.readbyqxmd.com/read/28283111/is-multiple-sclerosis-a-length-dependent-central-axonopathy-the-case-for-therapeutic-lag-and-the-asynchronous-progressive-ms-hypotheses
#1
REVIEW
Gavin Giovannoni, Gary Cutter, Maria Pia-Sormani, Shibeshih Belachew, Robert Hyde, Harold Koendgen, Volker Knappertz, Davorka Tomic, David Leppert, Robert Herndon, Claudia A M Wheeler-Kingshott, Olga Ciccarelli, David Selwood, Elisabetta Verdun di Cantogno, Ali-Frederic Ben-Amor, Paul Matthews, Daniele Carassiti, David Baker, Klaus Schmierer
Trials of anti-inflammatory therapies in non-relapsing progressive multiple sclerosis (MS) have been stubbornly negative except recently for an anti-CD20 therapy in primary progressive MS and a S1P modulator siponimod in secondary progressive MS. We argue that this might be because trials have been too short and have focused on assessing neuronal pathways, with insufficient reserve capacity, as the core component of the primary outcome. Delayed neuroaxonal degeneration primed by prior inflammation is not expected to respond to disease-modifying therapies targeting MS-specific mechanisms...
February 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28327329/ocrelizumab-in-multiple-sclerosis-markers-and-mechanisms
#2
Reinhard Hohlfeld, Edgar Meinl
No abstract text is available yet for this article.
April 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28450896/daclizumab-high-yield-process-in-the-treatment-of-relapsing-remitting-multiple-sclerosis
#3
REVIEW
Jana Lizrova Preiningerova, Marta Vachova
Daclizumab is a humanized monoclonal antibody that binds to the α subunit (CD25) of the interleukin-2 receptor and favorably modulates the immune environment in multiple sclerosis (MS). Blockage of CD25, among other effects, causes expansion and enhanced function of regulatory CD56(bright) natural killer cells, which seems to be the leading mechanism of action in MS. Phase II and III clinical trials have demonstrated that monthly subcutaneous injections of daclizumab high yield process (DAC HYP) 150 mg in patients with relapsing MS led to a significant reduction of annualized relapse rate and decreased number of contrast-enhanced lesions on brain magnetic resonance imaging...
January 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28450897/plasma-exchange-as-a-cost-effective-option-for-treating-guillain-barr%C3%A3-syndrome
#4
Eric J Buenz, Gareth J Parry, Annemarei Ranta
No abstract text is available yet for this article.
January 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28128038/management-of-anti-n-methyl-d-aspartate-nmda-receptor-encephalitis-in-children
#5
Madhu Nagappa, S Bindu Parayil, Anita Mahadevan, Sanjib Sinha, Pavagada S Mathuranath, Arun B Taly
No abstract text is available yet for this article.
April 2017: Journal of Child Neurology
https://www.readbyqxmd.com/read/28211007/daclizumab-a-review-in-relapsing-multiple-sclerosis
#6
REVIEW
Matt Shirley
Daclizumab (Zinbryta(®); previously known as daclizumab high-yield process) is a therapeutic monoclonal antibody that has recently been approved for the treatment of relapsing forms of multiple sclerosis (MS) in adults. Daclizumab is a humanized IgG1 monoclonal antibody directed against CD25, the alpha subunit of the high-affinity interleukin-2 receptor. As demonstrated in the phase III DECIDE trial, once-monthly subcutaneous daclizumab was superior to once-weekly intramuscular interferon (IFN) β-1a in reducing the clinical relapse rate and radiological measures of disease in patients with relapsing-remitting MS...
March 2017: Drugs
https://www.readbyqxmd.com/read/28002688/ocrelizumab-versus-placebo-in-primary-progressive-multiple-sclerosis
#7
RANDOMIZED CONTROLLED TRIAL
Xavier Montalban, Stephen L Hauser, Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, Giancarlo Comi, Jérôme de Seze, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer, Fred Lublin, Kottil W Rammohan, Krzysztof Selmaj, Anthony Traboulsee, Annette Sauter, Donna Masterman, Paulo Fontoura, Shibeshih Belachew, Hideki Garren, Nicole Mairon, Peter Chin, Jerry S Wolinsky
BACKGROUND: An evolving understanding of the immunopathogenesis of multiple sclerosis suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a humanized monoclonal antibody that selectively depletes CD20-expressing B cells, in the primary progressive form of the disease. METHODS: In this phase 3 trial, we randomly assigned 732 patients with primary progressive multiple sclerosis in a 2:1 ratio to receive intravenous ocrelizumab (600 mg) or placebo every 24 weeks for at least 120 weeks and until a prespecified number of confirmed disability progression events had occurred...
January 19, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28002679/ocrelizumab-versus-interferon-beta-1a-in-relapsing-multiple-sclerosis
#8
RANDOMIZED CONTROLLED TRIAL
Stephen L Hauser, Amit Bar-Or, Giancarlo Comi, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer, Fred Lublin, Xavier Montalban, Kottil W Rammohan, Krzysztof Selmaj, Anthony Traboulsee, Jerry S Wolinsky, Douglas L Arnold, Gaelle Klingelschmitt, Donna Masterman, Paulo Fontoura, Shibeshih Belachew, Peter Chin, Nicole Mairon, Hideki Garren, Ludwig Kappos
BACKGROUND: B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells. METHODS: In two identical phase 3 trials, we randomly assigned 821 and 835 patients with relapsing multiple sclerosis to receive intravenous ocrelizumab at a dose of 600 mg every 24 weeks or subcutaneous interferon beta-1a at a dose of 44 μg three times weekly for 96 weeks. The primary end point was the annualized relapse rate...
January 19, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28246062/epilepsy-with-myoclonic-atonic-seizures-and-chronic-cerebellar-symptoms-associated-with-antibodies-against-glutamate-receptors-n2b-and-d2-in-serum-and-cerebrospinal-fluid
#9
Ryuki Matsuura, Shin-Ichiro Hamano, Satoru Ikemoto, Yuko Hirata, Kotoko Suzuki, Kenjiro Kikuchi, Yukitoshi Takahashi
A 3-year-old boy with normal development presented with acute cerebellitis at one year and 10 months of age. His truncal ataxia resolved without treatment. He experienced a relapse of truncal ataxia and atonic seizures at 2 years and one month of age. Five months later, he experienced myoclonic atonic seizures. By 3 years of age, the truncal ataxia had become severe, and the frequency of myoclonic atonic seizures increased. Compared to controls, we found higher levels of anti-C-terminal GluN2B and anti-N terminal GluD2 antibodies in the serum, and anti-N terminal GluN2B and anti-C terminal GluD2 antibodies in the cerebrospinal fluid (CSF)...
February 27, 2017: Epileptic Disorders: International Epilepsy Journal with Videotape
https://www.readbyqxmd.com/read/24630282/long-term-neurocognitive-outcome-and-quality-of-life-in-pediatric-acute-disseminated-encephalomyelitis
#10
Agnese Suppiej, Elisa Cainelli, Giulia Casara, Ambra Cappellari, Margherita Nosadini, Stefano Sartori
BACKGROUND: Acute disseminated encephalomyelitis is an inflammatory-demyelinating disorder of the central nervous system usually with a monophasic course and a favorable neurological outcome. Long-term neurocognitive sequelae and quality of life have not yet been fully investigated. AIM: To examine neurocognitive outcome and quality of life in pediatric monophasic acute disseminated encephalomyelitis. METHODS: Of the 36 patients diagnosed with acute disseminated encephalomyelitis at our institution, six were lost to follow-up and eight relapsed (two with multiphasic forms and six with multiple sclerosis)...
April 2014: Pediatric Neurology
https://www.readbyqxmd.com/read/28109991/clinical-characteristics-treatments-and-outcomes-of-patients-with-anti-n-methyl-d-aspartate-receptor-encephalitis-a-systematic-review-of-reported-cases
#11
REVIEW
Le Zhang, Meng-Qian Wu, Zi-Long Hao, Siew Mun Vance Chiang, Kun Shuang, Min-Tao Lin, Xiao-Sa Chi, Jia-Jia Fang, Dong Zhou, Jin-Mei Li
Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis is a recently recognized autoimmune disorder which is responsive to immunotherapy. However, the outcomes of different immunotherapies have not been defined and there have been few studies that carried out a comparison among them. To provide an overview of the clinical characteristics, treatments, and outcomes of anti-NMDAR encephalitis, we systematically reviewed the literature in the PubMed, Medline, Embase, Cochrane Library, BioMedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), and Wan-fang databases...
March 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/24589025/tryptophan-immunoadsorption-for-the-treatment-of-autoimmune-encephalitis
#12
W Köhler, S Ehrlich, C Dohmen, M Haubitz, F Hoffmann, S Schmidt, R Klingel, A Kraft, T Neumann-Haefelin, H Topka, O Stich, A Baumgartner, C Fassbender
BACKGROUND AND PURPOSE: Detection of autoantibodies against neuronal surface antigens and their correlation with the pattern and severity of symptoms led to the definition of new autoimmune-mediated forms of encephalitis and was essential for the initiation of immunotherapies including plasma exchange. The elimination of autoantibodies using selective immunoadsorption (IA) is a pathophysiologically guided therapeutic approach but has not yet been evaluated in a separate analysis. METHODS: A retrospective analysis was performed of patients with autoimmune encephalitis who were treated with tryptophan IA in six neurological clinics between 2009 and 2013...
January 2015: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/22772674/a-multidisciplinary-approach-to-the-treatment-of-anti-nmda-receptor-antibody-encephalitis-a-case-and-review-of-the-literature
#13
REVIEW
Andrea Mann, Nikolas Mata Machado, Ni Liu, Abdul-Hussein Mazin, Kenneth Silver, Khalid I Afzal
Anti-NMDAR (N-methyl-d-aspartate receptor) encephalitis is a novel autoimmune and paraneoplastic disease often presenting as acute psychosis. Few studies exist in the psychiatric literature on neuroimmunity and behavioral management. This article reviews the epidemiology, diagnosis, pathophysiology, and management of this disease from a neuropsychiatric perspective. Patients have potential for near-complete recovery with early diagnosis and intervention. In addition to immune-suppression and tumor removal, electroconvulsive therapy may be an important tool in treatment of the underlying process in cases developing life-threatening catatonia...
2012: Journal of Neuropsychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/26709797/efficacies-of-treatments-for-anti-nmda-receptor-encephalitis
#14
REVIEW
Hsiuying Wang
Treatments for anti-N-methyl-D-aspartate (NMDA) receptor encephalitis include immunotherapy with steroids, intravenous immunoglobulin, plasma exchange, or plasmapheresis as first-line treatments, immunotherapy with rituximab or cyclophosphamide as second-line treatments, and tumor removal. In this systematic review, we evaluated previous studies and examined the association between certain microRNAs and anti-NMDA receptor encephalitis to investigate the performance of different treatment combinations. The efficacies of different combinations of treatments classified into the following four categories were compared: (I) intravenous immunoglobulin administration, (II) plasmapheresis or plasma exchange, (III) treatment with rituximab or cyclophosphamide and (IV) tumor removal...
January 1, 2016: Frontiers in Bioscience (Landmark Edition)
https://www.readbyqxmd.com/read/20517615/reversible-brain-atrophy-in-anti-nmda-receptor-encephalitis-a-long-term-observational-study
#15
Takahiro Iizuka, Shintaro Yoshii, Shinichi Kan, Junichi Hamada, Josep Dalmau, Fumihiko Sakai, Hideki Mochizuki
The long-term neuroimaging correlates of clinical recovery have not been described in anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. The aim of the study is to evaluate the long-term outcome of brain atrophy in anti-NMDAR encephalitis. Patients were two women (ages 17 and 33 years) with severe anti-NMDAR encephalitis resulting in decreased level of consciousness, autonomic instability, hypoventilation, and dyskinesias requiring continuous infusion of anesthetic agents for 6-7 months. Brain MRI and cerebral blood flow SPECT obtained at the time of maximal neurological disability were compared with similar studies obtained 5-7 years later...
October 2010: Journal of Neurology
https://www.readbyqxmd.com/read/20819992/pearls-oy-sters-electroconvulsive-therapy-in-anti-nmda-receptor-encephalitis
#16
H M H Braakman, V M P Moers-Hornikx, B M G Arts, R M M Hupperts, J Nicolai
No abstract text is available yet for this article.
September 7, 2010: Neurology
https://www.readbyqxmd.com/read/21831679/successful-treatment-of-two-paediatric-cases-of-anti-nmda-receptor-encephalitis-with-cyclophosphamide-the-need-for-early-aggressive-immunotherapy-in-tumour-negative-paediatric-patients
#17
Pawan Kashyape, Ellen Taylor, Joanne Ng, Deepa Krishnakumar, Fenella Kirkham, Andrea Whitney
We describe the clinical course and treatment of three unrelated female patients ranging in age from 27 months to 14 years with anti-NMDA receptor encephalitis. The third case is reported as an addendum to the paper. None of the cases were paraneoplastic. All received initial immunotherapy consisting of steroids and IVIg, and two of them received 3 and 8 plasma exchanges respectively, without consistent or sustained clinical improvement. All three girls were then treated with monthly cycles of Cyclophosphamide...
January 2012: European Journal of Paediatric Neurology: EJPN
https://www.readbyqxmd.com/read/25952599/-reversible-cortical-atrophy-secondary-to-anti-nmda-receptor-antibody-encephalitis
#18
REVIEW
Antonio Bravo-Oro, Danae Acosta-Yebra, Ilse P Grimaldo-Zapata, Guillermo Reyes-Vaca
INTRODUCTION: Anti-N-methyl-D-aspartate (NMDA) receptor antibody encephalitis was initially described as a paraneoplastic syndrome associated to ovarian teratomas. Yet, an increasing number of reports are being published involving cases of young women and children with signs and symptoms of an autoimmune encephalopathy, in 40-50% of the cases secondary to a viral infection. Clinically, it is characterised by a progressive picture of psychiatric manifestations, convulsive seizures, dyskinesias and dysautonomias...
May 16, 2015: Revista de Neurologia
https://www.readbyqxmd.com/read/24980905/sudden-and-isolated-broca-s-aphasia-a-new-clinical-phenotype-of-anti-nmda-receptor-antibodies-encephalitis-in-children
#19
Kumaran Deiva, Maria Carmela Pera, Hélène Maurey, Pascale Chrétien, Frédérique Archambaud, Viviane Bouilleret, Marc Tardieu
BACKGROUND: Anti NMDA receptor (anti NMDAR) encephalitis is a well-characterized entity in children associating movement disorders, psychiatric features and speech difficulties. Novel phenotypes have been described in adults. METHODS AND RESULTS: A 4-year-old girl presented partial seizures which evolved towards sudden and isolated Broca's aphasia. Anti NMDAR antibodies were positive in CSF and serum confirming anti NMDAR encephalitis. Clinical recovery was observed after a specific treatment...
November 2014: European Journal of Paediatric Neurology: EJPN
https://www.readbyqxmd.com/read/26348805/a-case-of-anti-nmda-receptor-encephalitis-treated-with-ect
#20
Kristin C Jones, Ann C Schwartz, Adriana P Hermida, David A Kahn
We describe the case of a 17-year-old male who presented with acute onset of seizures and malignant catatonia with psychosis, agitation, and hypermetabolism, who responded to electroconvulsive therapy (ECT). Soon after he began to respond, he was diagnosed with anti-N-methyl-D-aspartate (NMDA) receptor encephalitis and then given immunosuppressive therapy. Anti-NMDA receptor encephalitis is an increasingly recognized autoimmune disorder that often presents with neuropsychiatric symptoms. The mainstays for treatment have been early diagnosis, tumor work-up and removal if found, and initiation of immunosuppressive therapy...
September 2015: Journal of Psychiatric Practice
label_collection
label_collection
7674
1
2
2017-02-07 21:03:16
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"